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Talimogen laherparepvec (TVEC) is an oncolytic virus
that has been approved recently for the treatment of
stage IIIb, IIIc, and IVa melanoma by regulatory agencies
such as Food and Drug Administration, Swissmedic, and
EMA. TVEC is an intralesional applicated genetically
modified Herpes simplex virus type I that replicates
selectively in tumor cells [1].
Most common side effects during TVEC treatment
include chills, pyrexia, nausea, and injection-site pain.
There are known skin toxicities including vitiligo and
cellulitis [1].
Here, we report a case of an interstitial granulomatous
dermatitis (IGD) in a patient treated with TVEC.
A 31-year-old healthy man was diagnosed with a melan-
oma of the skin located on the thigh left in 2008. Breslow
thickness was 0.8 mm; therefore, only wide excision was
performed. In May 2014, the patient developed palpable
lymphnode metastases in the left groin, without distant
metastases, confirmed by PET-CT. He underwent
complete lymphadenectomy, followed by adjuvant irra-
diation therapy. In December 2014, liver metastases were
detected. The patient was included in the AMGEN
20110265-trial [2]. As per protocol, treatment started with
TVEC only first (week − 5 and − 2), whereas
Pembrolizumab was added at week 0. The patient had
one injectable lesion in the left inguina, which was
injected with 0.5 ml TVEC. Twelve days later, he
developed fever, chills, and nausea. Isolated elevation of
C-reactive protein of 186 mg/l was detected; an infectious
focus was not found but suspected. Therefore, treatment
with amoxicillin/clavulanic acid was initiated. The same
day, unilateral reddish-bluish, slightly infiltrated lesions
partly arranged in a linear pattern developed on the left
lower leg (Fig. 1). The rash spread over the entire leg up
to the buttocks during the next 4 days. The biopsy
showed a perivascular and interstitial CD-68-positive
mononuclear infiltrate with granulomatous aspects
(Fig. 2) and discrete edema. Immunohistochemical
stainings showed CD68-positive macrophages in the
dermis, lymphocytes were mostly CD3-positive and
CD4-positive, and some were found to be CD8-positive.
On the basis of the clinical and histological features, IGD
was diagnosed.
Topical mometasone was used as treatment; the lesions
showed rapid improvements. Unfortunately, the patient
developed further rapid tumor progression and died
despite one infusion of pembrolizumab.
TVEC is a sophisticated genetically modified organism
treatment tool with deletion of the ICP34.5 gene seg-
ment, allowing replication in tumor cells, and deletion of
ICP47, which prevents ICP47 from blocking antigen
presentation. Two copies of human granulocyte-
macrophage colony-stimulating factor (GM-CSF) under
the control of a cytomegalovirus promotor are inserted to
promote the secretion of this cytokine in the tumor
microenvironment.
Fig. 1
Clinical findings. Reddish-bluish, slightly infiltrated lesions partly
arranged in a linear pattern on the left lower leg.
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The replication of TVEC results in an immunogenic cell
death and the activation of innate and adaptive immune
responses including the activation of macrophages [3].
IGD is a macrophage-mediated dermal inflammatory
disease associated with autoimmune syndromes such as
rheumatoid arthritis [4]. GM-CSF shifts the phenotype of
macrophages toward a proinflammatory direction and
favors differentiation into dendritic cells [5].
In animal models of multiple sclerosis, proinflammatory
CCR2(+ )Ly6C(hi) monocytes were found to be the
target cells of GM-CSF signaling [6]. GM-CSF produc-
tion is upregulated in TVEC-injected lesions, resulting in
macrophage activation locally as reported by Long and
colleagues and possibly also in regional dermal activation
that presents clinically as ICD. Another possible con-
tributing factor may be the underlying metastatic
melanoma as malignancies can trigger IGD [4].
This is the first case, to our knowledge, of IGD during
intralesional TVEC therapy. This immune-related
adverse event might help us to improve our under-
standing of dermal granulomatous inflammation
including the IGD. The diagnosis of ICD is made on the
basis of the correlation of clinical and histological
features. Therefore, we recommend skin biopsies if
unspecific cutaneous lesions occur during TVEC-based
immunotherapy.
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Fig. 2
Histopathology. CD68-staining with dermal accumulation of a
CD68-positive mononuclear infiltrate.
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